<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33120">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675491</url>
  </required_header>
  <id_info>
    <org_study_id>DS6051-A-J102</org_study_id>
    <nct_id>NCT02675491</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors</brief_title>
  <official_title>Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors Harboring Either a ROS1 or NTRK Fusion Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of
      DS-6051b in Japanese subjects with advanced solid malignant tumors harboring either a ROS1
      or NTRK fusion gene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is single arm study with DS-6051b in approximately 9 subjects with advanced solid
      malignant tumors harboring either a ROS1 or NTRK fusion gene. Safety and tolerability,
      pharmacokinetics (PK), MTD/RP2D (maximum tolerated dose/recommended phase 2 dose) and
      preliminary efficacy of DS-6051b will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number and severity of adverse events</measure>
    <time_frame>Day 1 through 28 days after last dose</time_frame>
    <description>number and severity of treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of DS-6051a</measure>
    <time_frame>Days 1 and 15 of Cycle 1</time_frame>
    <description>Maximum concentration (Cmax), time to maximum plasma concentration (Tmax), area under the concentration-time curve (AUC) and CL/F for DS-6051a (a free base form of DS-6051b) will be assessed on Days 1 and 15 of Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of DS-6051a</measure>
    <time_frame>Days 1 and 15 of Cycle 1</time_frame>
    <description>Maximum concentration (Cmax), time to maximum plasma concentration (Tmax), area under the concentration-time curve (AUC) and CL/F for DS-6051a (a free base form of DS-6051b) will be assessed on Days 1 and 15 of Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of DS-6051a</measure>
    <time_frame>Days 1 and 15 of Cycle 1</time_frame>
    <description>Maximum concentration (Cmax), time to maximum plasma concentration (Tmax), area under the concentration-time curve (AUC) and CL/F for DS-6051a (a free base form of DS-6051b) will be assessed on Days 1 and 15 of Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance (CL/F) of DS-6051a</measure>
    <time_frame>Days 1 and 15 of Cycle 1</time_frame>
    <description>Maximum concentration (Cmax), time to maximum plasma concentration (Tmax), area under the concentration-time curve (AUC) and CL/F for DS-6051a (a free base form of DS-6051b) will be assessed on Days 1 and 15 of Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with dose-limiting toxicities</measure>
    <time_frame>21 days following the first dose of treatment</time_frame>
    <description>to determine maximum tolerated dose/recommended phase 2 dose</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Advanced Solid Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>DS-6051b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: DS-6051b 400 mg or 800 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-6051b</intervention_name>
    <description>Drug: DS-6051b 400 mg or 800 mg daily</description>
    <arm_group_label>DS-6051b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced solid malignant tumors that are refractory to standard therapy or for which
             no standard therapy is available.

          -  An Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

        Exclusion Criteria:

          -  Previously had or currently has any of the following diseases:

        Cardiac failure (NYHA Functional Classification â‰¥ Class III), myocardial infarction,
        cerebral infarction, unstable angina, arrhythmia requiring treatment, coronary/peripheral
        artery disease, pulmonary thrombosis, uncontrolled deep vein thrombosis, clinically severe
        thromboembolic event, or autoimmune disease requiring treatment.

          -  Previously had or currently has clinically severe pulmonary disease (eg, interstitial
             pneumonia, pneumonitis, pulmonary fibrosis, radiation pneumonia).

          -  Severe or uncontrolled concomitant disease.

          -  Clinically active brain metastases or central nervous system tumor requiring steroid
             or anticonvulsant treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>February 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumor</keyword>
  <keyword>DS-6051b</keyword>
  <keyword>ROS1</keyword>
  <keyword>NTRK</keyword>
  <keyword>refractory to standard therapy</keyword>
  <keyword>no standard therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
